Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.

Front Oncol · 2021 · PMC8580328 · PMID 34778031

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

an increasing trendp = 0.064so close (0.05 < p ≤ 0.1)

Moreover, authors observed an increasing trend in the median PFS from 4.37 months in the EXTREME arm to 6.5 months in the paclitaxel, carboplatin, and cetuximab arm ( p = 0.064) ( 14 ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.